A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia

Trial Profile

A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs DFP 10917 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Delta-Fly Pharma
  • Most Recent Events

    • 02 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 02 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top